Bigul

Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
04-03-2020
Bigul

Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed a copy of press release dated March 3, 2020 titled 'Zydus receives Phase I clinical trial permission for ZYBK2 from DCGI'.
03-03-2020
Bigul

Cadila Healthcare Ltd - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate

Loss of Share Certificate / Issue of Duplicate Share Certificate.
26-02-2020
Bigul

Zydus Cadila launches research programme to develop vaccine for coronavirus

The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.
15-02-2020
Bigul

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed a copy of press release dated February 15, 2020 titled 'Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19)'.
15-02-2020
Bigul

Earnings Call Transcript - Cadila Healthcare

Full Earnings Transcript: Conference Call between Management and Analysts
14-02-2020
Bigul

Zydus Cadila gets USFDA nod to market Mesalamine suppositories

Zydus Cadila on Thursday said it has got final approval from the US health regulator to market Mesalamine suppositories. The drug is used to treat ul
13-02-2020
Bigul

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed a copy of press release dated February 13, 2020 titled 'Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg'.
13-02-2020
Bigul

Zydus Cadila gets USFDA nod to market cream for treating skin conditions

Zydus Cadila on Tuesday said it has received approval from the United States Food and Drug Administration (USFDA) to market generic Fluocinonide cream
11-02-2020
Bigul

Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation

Please find enclosed the investor presentation to be made to select investors on Wednesday February 12, 2020 at Mumbai in IIFL Investor Conference.
11-02-2020
Next Page
Close

Let's Open Free Demat Account